ERBB2 and cancer: Patients who received radiotherapy for BRM were more likely to have TNBC or ERBB2-positive cancer than HR-positive/ERBB2-negative cancer (P < .001) and were younger than those who did not receive radiotherapy for BRM (P < .001).